Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
View Top Employees from TheratechnologiesWebsite | http://www.theratech.com |
Ticker | TH |
Revenue | $46 million |
Employees | 51 (41 on RocketReach) |
Founded | 1993 |
Phone | (514) 336-7800 |
Fax | (514) 331-9691 |
Technologies |
JavaScript,
HTML,
Google Analytics
+28 more
(view full list)
|
Industry | Pharmaceuticals, Biotechnology, Drug Discovery, Healthcare, Science and Engineering, Pharmaceutical, Health Care, Therapeutics |
Web Rank | 7 Million |
Keywords | Theratechnologies, Theratechnologie, Thera Technologies, Theratechnologies Inc. Investor Relations, "Theratechnologies" Investor Relations |
Competitors | CellCentric, NeuTec Pharma Ltd., NuPathe Inc., Satsuma Pharmaceuticals, Inc., VIVUS LLC |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 33 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Theratechnologies employee's phone or email?
The Theratechnologies annual revenue was $46 million in 2024.
Yves Rosconi is the President and Chief Executive Officer of Theratechnologies.
41 people are employed at Theratechnologies.
Theratechnologies is based in Montréal, Quebec.
The NAICS codes for Theratechnologies are [32541, 33, 3254, 325, 32].
The SIC codes for Theratechnologies are [283, 28].